14.12.2012 - After decades of deadlock, Europe is finally set to get a new unified patent. This week the Competitiveness Council and MEPs adopted the draft law.
Provided the draft law will be signed by at least 13 EU member states, EU patents must be only translated into three languages cutting the cost drastically. Today, two thirds of the patent cost of €36,000 is translation cost. The new unitary patent is calculated to cost a maximum of only €6,425, with the costs of translation set to range from €680 to €2,380. However, this is still twice as expensive as an US patent. “Today’s vote is good news for the EU economy and especially for small and medium-sized enterprises (SMEs),” said MEP Bernhard Rapkay.
Italian MEP Raffaele Baldassarre, who had been leading negotiations on the new translation regime, described the current cost burden as “effectively a tax on innovation. We have to understand that there is a need out there to facilitate innovation in the EU."
Under the new scheme, patent applications will have to be made in either English, French or German – and will be made available in the same three languages. MEPs also voted to fully reimburse translation costs for EU-based SMEs, non-profit organisations, universities and public research organisations - something expected to benefit small high-tech firms in particular.Renewal fees, which are responsible for much of the overall cost of the current European system, will also be set at a level to help SMEs.
“Spain and Italy have so far opted out of the unitary patent package, but could join in the decision-making process at any time,” the Parliament says. “This procedure was used to break a deadlock, mainly due to language issues, that lasted over thirty yearsThe agreement is expected to be signed in February next year, and it will come into force on 1 January 2014 or when at least 13 member states including the UK, France and Germany have ratified it. Patents on plants have been excluded from the law, previously. The legislation still has to be formally adopted by the Council, but this will take place shortly.
26.08.2016 Adocia said it would discontinue its diabetic foot ulcer programme after its lead product BioChaperone PDGF disappointed in Phase III. The French company will turn the focus on its earlier-stage products.
24.08.2016 Pharma major Pfizer is putting the cherry on top of its multi-billion-dollar takeover of Medivation with the acquisition of AstraZeneca’s antibiotics for a cool US$1.5bn. With the divestment, AZ aims to further sharpen its focus.
23.08.2016 Cambridge University-allied investor Cambridge Innovation Capital has raised £75m (€87m) to reinvest in technology and healthcare companies. Among the backers were Woodford Investment and Winton Ventures.
19.08.2016 Together with partner Johnson & Johnson, Danish biotech Genmab is now one step closer to FDA approval with its combination treatment for multiple myeloma after its submission of a supplemental Biologics License Application. In July, Genmab was granted a Breakthrough Therapy Designation (BTD) for its blood cancer therapy.
17.08.2016 Philip Hammond, the UK’S chancellor has announced the government will guarantee funding for EU-backed "structural and investment fund" projects whose timelines extend beyond the UK’s departure from the EU, provided the projects are signed prior to this year's Autumn Statement on the UK budget. The decision ensures continued funding for farmers, companies and institutions involved in the EU’s Horizon 2020 project. The move could cost the UK government up to £6bn (€6.9bn).
15.08.2016 Back in April, the American FDA gave the green light for the colorectal cancer-screening test Epi procolon. Now Berlin-based diagnostics specialist Epigenomics is considering a secondary listing in the US. A draft of the required registration document was confidentially submitted to the US Securities and Exchange Commission (SEC).
09.08.2016 Hungarian Gedeon Richter and Irish Allergan are staying on course in the face of dissappointing Phase III results for depression drug cariprazine. The partners will now begin another Phase III study needed for approval.
08.08.2016 Araclon Biotech’s Alzheimer’s vaccine ABvac40 is going forward into Phase II after showing a good safety profile in Phase I. The promising trial results were presented at the Alzheimer’s Association International Conference.
FILTRODISC™ BIO SD is a filtration system which removes particles (e.g. cells, bacteria, yeast), impurities (e.g. HCP, DNA) and other turbid matter from process liquids (e.g. fermentation broths). more